Amgen Inc. and Ortho Biotech Products LP preempted an FDA advisory panel review of Aranesp, Epogen and Procrit by strengthening the anemia drugs' black-box warnings with new safety language about the risks of using the products in patients with breast and cervical cancers. (BioWorld Today)